STOCK TITAN

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Novocure (NVCR) executives William Doyle and Ashley Cordova will participate in the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023. The company will host a fireside chat and one-on-one meetings with investors. Live webcasts will be available on the Investor Relations page of Novocure’s website, with replays accessible for at least 14 days. Novocure uses its Investor Relations website to disclose material non-public information and comply with Regulation FD.
Positive
  • None.
Negative
  • None.

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside chat at 3:30 p.m. EST, as well as one-on-one meetings with investors throughout the event.

Live audio webcasts of these presentations can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.

Novocure’s corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations. Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 23, 2023, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Investors:

Ingrid Goldberg

investorinfo@novocure.com

610-723-7427

Media:

Leigh Labrie

media@novocure.com

610-723-7428

Source: Novocure

FAQ

When will Novocure (NVCR) executives participate in the 35th Annual Piper Sandler Healthcare Conference?

William Doyle and Ashley Cordova will participate on November 29, 2023.

Where can the live webcasts of Novocure (NVCR) presentations be accessed?

The live webcasts can be accessed on the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations.

How long will the replays of the presentations be available?

Replays will be accessible for at least 14 days following the event.

What is Novocure’s (NVCR) usage of its Investor Relations website?

Novocure uses its Investor Relations website to disclose material non-public information and comply with Regulation FD.

NovoCure Limited

NASDAQ:NVCR

NVCR Rankings

NVCR Latest News

NVCR Stock Data

2.05B
97.90M
9.26%
84.94%
5.24%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ST. HELIER